CANGRELOR相关论文
坎格瑞洛为注射给药的P2Y_(12)血小板受体抑制剂,该药直接起效并且作用可逆,具有起效快、失效快的特点。欧洲药品管理局(European ......
新型抗血小板药物坎格瑞洛是首个速效、静脉使用的抗血小板药物,可逆性地与P2Y12受体结合,发挥抗血小板作用,与传统的抗血小板药物......
目的探讨抗血小板药Cangrelor缓解博来霉素诱导的小鼠肺纤维化的作用及机制。方法整体动物实验以博来霉素(BLM)3mg·kg^-1诱导......
Patients listed for organ transplant frequently have severe coronary artery disease(CAD),which may be treated with drug ......
Antiplatelet therapy is the cornerstone of the therapeutic arsenal in coronary artery disease.Thanks to a better underst......
